



THE JOURNAL OF  
**CLINICAL PSYCHIATRY**

THE OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF CLINICAL PSYCHOPHARMACOLOGY

## **Supplementary Material**

**Title:** Repetitive Transcranial Magnetic Stimulation for Treatment-Resistant Depression: Mismatch of Evidence and Insurance Coverage Policies in the United States

**Authors:** Cory R. Weissman, MD; Richard A. Bermudes, MD; Jeffrey Voigt, MBA, MPH; Conor Liston, MD, PhD; Nolan Williams, MD; Daniel M. Blumberger, MD, MSc; Paul B. Fitzgerald MD, PhD; and Zafiris J. Daskalakis, MD, PhD

**DOI Number:** 10.4088/JCP.22com14575

### **List of Supplementary Material**

1. [Table 1](#) Insurance Requirements by Plan for Approval of an Initial 6-Week Course of rTMS for MDD

### **Disclaimer**

This Supplementary Material has been provided by the author(s) as an enhancement to the published article. It has been approved by peer review; however, it has undergone neither editing nor formatting by in-house editorial staff. The material is presented in the manner supplied by the author.

Supplementary Table 1. Insurance Requirements by Plan for Approval of an Initial 6-week Course of rTMS for MDD

Insurance Plans	Estimated Number of Members/ State Operations	Depression Severity Requirement (1) Not specified (NS); Moderate (M); Severe (S); Moderate or Severe (M-S)	Number of Failed Psychopharmacologic Agents Requirement (2) (Antidepressants, Augmentation trials) <sup>1</sup>	Number of Antidepressant Trials Not Tolerated Requirement (3)	Failed Psychotherapy Requirement (4)	Prior Authorization Requirement	Guideline for Treatment After Failure of One Medication Trial
Clinical TMS Society Guidelines	--	M-S	1 (1,0)	2	No	--	1 <sup>st</sup> Line
FDA Clearance	--	MDD (no severity specified)	1 or more	NS	--	--	1 <sup>st</sup> Line
Traditional Medicare Enrollment (2021)	36 million						
First Coast Service Options L34522 Updated 12/11/22	FL, Puerto Rico, US Virgin Islands	S	1 (1,0)	1	No	No	1 <sup>st</sup> Line
Novitas 34998 Updated 12/11/22	AR, CO, DE, DC, MD, NJ, NM, OK, PA, LA, TX	S	1 (1,0)	1	No	No	1 <sup>st</sup> Line
Noridian L37086 Updated 12/1/2019	AK, AZ, CA, HI, ID, ND, NV, MT, OR, SD, UT, WA, WY, American Samoa, Guam, Northern Mariana Islands	S	1 (1,0)	2	Yes	No	1 <sup>st</sup> Line
Palmetto GBA L4869 Updated 6/9/22	AL, GA, NC, TN, SC, VA, WV	S	2 (2,1)	2	Yes	No	2 <sup>nd</sup> Line
Wisconsin Physicians Service Government Health Administrators L34641 Updated 10/17/2022	IA, KS, MO, NE, IN, MI	S	2 (2,0)	2	Yes	No	2 <sup>nd</sup> Line
CGS Administrators, LLC L36569 Updated 1/5/2023	KY, OH	S	2 (2,0)	2	Yes	No	2 <sup>nd</sup> Line
National Government Services Inc L33398 Updated 10/1/2020	IL, MN, WI, CT, NY, ME, MA, NH, RI, VT	NS	4 (4,2)	4	Yes	No	4 <sup>th</sup> Line
Commercial Insurance Plans							
Aetna	39 million/ All 50 States	S	2 (2,1)	2	Yes	Yes	2 <sup>nd</sup> -3 <sup>rd</sup> Line
Cigna	17M/ AZ, CA, CO, CT, GA, MO, NC, SC, TN, TX MD, FL	M-S	2 (2,0)	2	Yes	Yes	2 <sup>nd</sup> Line
United Health Care/Optum	49.5 million/ All 50 States	S	4 (4,0)	4	Yes	Yes	4 <sup>th</sup> Line
Humana	20 million/ AZ, CO, FL	S	4 (4,0)	4	Yes	Yes	4 <sup>th</sup> Line
Centene (Magellan)	FL, LA, NW, VI, WY, PN	S	4 (4,0)	2	Yes	Yes	4 <sup>th</sup> line
Centene (Health Net)	CA	M-S	4 (4,2)	4	Yes	Yes	4 <sup>th</sup> Line
Tufts	MA	NS	4 (2,2)	4	Yes	Yes	3 <sup>rd</sup> -4 <sup>th</sup> Line

Blue Cross Blue Shield (BCBS) Association							
Heath Care Service Corporation	IL, MN, NW, OK, TX	M-S	2 (2,0)	NS	Yes	Yes	2 <sup>nd</sup> Line
Anthem	42 million/ CA, CO, CT, GA, IN, KY, ME, MI, NV, NH, NY, OH	NS	2 (2,0)	4	No	Yes	2 <sup>nd</sup> Line
Premiera Blue Cross Blue Shield of Alaska	2.6 million/ AK, WA	M-S	2 (2,1)	2	No	Yes	2 <sup>nd</sup> Line
Blue Shield of California	CA	S	2 (2,0)	2	Yes	Yes	2 <sup>nd</sup> Line
Care First Blue Cross Blue Shield	DC, MD, VA	NS	2 (2,0)	NS	No	Yes	2 <sup>nd</sup> Line
Blue Cross Blue Shield MN	MN	S	3 (3,1)	4	Yes	Yes	3 <sup>rd</sup> Line
Providence	AK, CA, MN, NM, OR, TX, WA	S	3 (3,0)	3	Yes	Yes	3 <sup>rd</sup> -line
High Mark Blue Cross Blue Shield	DE, PN, WV	S	4 (2,2)	4	Yes	Yes	2 <sup>nd</sup> -4 <sup>th</sup> Line
Multiple Blue Cross and Blue Shield Plans, Blue KC, Florida Blue, Scan Health Plan, High Mark Blue Cross, Blue Shield	AL, AR, KS, LA, MI, FL, MO, WY, VT, ID, NC, DE, PN, WV,	S	4 (2,2)	4	Yes	Yes	2 <sup>nd</sup> -4 <sup>th</sup> Line
Regence Blue Cross Blue Shield	ID, OR, UT, WA	NS	3 (3,0)	3	Yes	Yes	3 <sup>rd</sup> Line
Blue Cross Blue Shield HA, MA, Excellus,	HA, MA, NY	S	4 (4,0)	3	Yes	Yes	4 <sup>th</sup> Line
Blue Shield Blue Cross Federal Program		S	4 (2,2)	4	Yes	No	2 <sup>nd</sup> -4 <sup>th</sup> Line

<sup>1</sup>Some policies specify that medication trials must involve combined antidepressant treatment, or medications from at least two different classes prescribed as separate trials, or failure of a trial that involves an antidepressant agent plus an augmenting agent.

How to interpret the above table: We reviewed insurance TMS coverage policies publicly available on the web from 2/1/2023- 2/7/2023. Coverage for TMS services is based on **(1)** a confirmed diagnosis of MDD with either moderate or severe symptoms documented on a validated rating scale, **(2)** Resistance to treatment with psychopharmacological agents as demonstrated by a lack of clinically significant response (<50% reduction in symptoms) **or (3)** Inability to tolerate psychopharmacological agents **and (4)** lack of response to evidence-based psychotherapy as documented by standardized rating scales that reliably measure depressive symptoms. Policies shaded green are consistent with FDA clearance and CTMSS guidelines, and they consider TMS 1<sup>st</sup> line treatment after failing one pharmacological treatment for MDD. Policies in yellow are moderately restrictive of TMS treatment compared to FDA clearance and CTMSS guidelines; they consider TMS after two pharmacological trials (i.e., TMS is 2<sup>nd</sup> Line after one drug failure). Policies in red are overly restrictive compared to the FDA clearance and CTMSS guidelines, and they require multiple pharmacological agents and a high level of treatment resistance before approving TMS.